Ingabe i-Glucosamine Iphumelela Ekuphatheni I-Knee Osteoarthritis?

Kuyinto engeza impikiswano, ngakho-ke gcina lezi zindwangu engqondweni

I-Glucosamine isisindo sokudla ngezinye izikhathi esetshenziswa ukunciphisa ubuhlungu be- knee osteoarthritis (OA). Uma sekudumile kakhulu, ukusetshenziswa kwayo manje sekudlulela, ikakhulukazi ngenxa yemiphumela ehlanganisiwe ehambisana nalokhu okuzuzwayo kweqiniso komthengisi.

Uma uthatha i-glucosamine noma ucabangela ukuhlolwa kwesilwane (ngaphansi kokunakekelwa kukadokotela wakho) Yebo, kukhona ama-tidbits amahlanu okumele agcine engqondweni:

I-Tidbit # 1: I-Glucosamine Ngokungokwemvelo Kutholakala Ezingxenyeni

I-Glucosamine yinto engokwemvelo (ebizwa ngokuthi i-amino ashukela) etholakala enhlobonhlobo ye- articular cartilage kanye ne- synovial fluid , kokubili ehlanganisa amalungu akho. Esikhathini se-osteoarthritis, i-carticlage ye-articular emajoyini akho iyawohloka, okwenza ubuhlungu nokuqina. Ubuhlungu bungaba bukhulu kakhulu njengoba uqwanga luba lukhuni kakhulu kangangokuba amathambo aqala ukuxubana ngomunye nomunye.

I-Tidbit # 2: I-Glucosamine Ayilawulwa Njengedakamizwa

E-United States, i-glucosamine ithengiswa njengesengezo sokudla. Lokhu kusho ukuthi ilawulwa yi-United States Food and Drug Administration (FDA) njengomkhiqizo wokudla, ngokumelene nomuthi wokugulisa noma umuthi odokotela abaningi.

Ngalokho, yize i-glucosamine yinto engokwemvelo ye-cartilage, akusho ukuthi ukuthatha kuphephile ngokuphelele. Empeleni, i-glucosamine ingashintsha amazinga kashukela egazi futhi ingase ihlanganyele neminye imithi efana ne-Coumadin (i-warfarin) enegazi.

Njengoba njalo, qiniseka ukuthi uthatha kuphela isidakamizwa, kufaka phakathi izithako, ngaphansi kokunakekelwa udokotela wakho.

I-Tidbit # 3: I-Glucosamine Ngeke Iphumelele Knee Osteoarthritis Yakho

Ngesikhathi ucwaningo lwama-cartilage cell luthola ukuthi i-glucosamine ingathuthukisa ukuphindaphinda kwe-cartilage futhi igweme izinqubo zokuvuvukala eziholela ekulimaleni kwe-cartilage, le datha ye-laboratory ayizange iguqule ekuzuzeni umtholampilo.

Ucwaningo olukhulu lokuqala e-United States oluhlolisisa imiphumela yesikhashana ye-glucosamine (nge knee osteoarthritis) ibizwa ngokuthi yi-GAIT trial (Glucosamine Arthritis Intervention Trial).

E-GAIT, abahlanganyeli abangaphezu kuka-1500 abane-knee-osteoarthritis babelwa ngezikhathi ezithile kwelinye lamacembu amahlanu okulashwa:

Imiphumela evela ocwaningweni lwe-GAIT yabonisa ukuthi ababambiqhaza abasebenzisa i-NSAID celecoxib bahlangabezana nokuphumula okubuhlungu okubaluleka okuhambisana nobukhulu be-placebo.

Kwakungekho ukungafani okuphawulekayo phakathi kweminye imithi ehlolwayo ne-placebo.

Yize, kwabanye abahlanganyeli bezobuhlungu obunomthelela obunzima, i-glucosamine ehlangene ne-chondroitin sulfate inikeze ukukhululeka okukhulu kobuhlungu uma kuqhathaniswa ne-placebo. Nokho, abacwaningi bokucwaninga, bathi, ngoba ubukhulu bale nhlangano encane babuncane kakhulu, lokhu kutholwa kufanele kubhekwe njengokuqala futhi kudinga ukuqinisekiswa ezifundweni zocwaningo ezizayo.

Kwababambiqhaza abanezinhlungu zomzimba ezincane (ngokungafani nokulinganisela noma okunzima) i-glucosamine ne-chondroitin sulfate ndawonye noma eyedwa ayinikezanga ukukhululeka okukhulu kobuhlungu.

I-Tidbit # 4: Kunezinhlobo ezimbili ze-Glucosamine

Kubalulekile ukuqaphela ukuthi i-glucosamine inganikezwa ngezinhlobo ezimbili ezihlukahlukene zethusi, i-hydrochloride noma i-sulfate. Ucwaningo lwe-GAIT (okukhulunywe ngenhla) lisetshenziselwa i-glucosamine hydrochloride. Ngokuthakazelisayo, izifundo eziye zabonisa ezinye izinto ezinokwenzeka, nakuba ezincane, ezisetshenziswa glucosamine sulfate ukuphatha i-osteoarthritis esikhundleni se-glucosamine hydrochloride.

Isibonelo, isifundo esikhulu ku- International Journal of Clinical Practice sihlolisise iziguli ezingaphezu kuka-3000 nge-knee osteoarthritis ngaphakathi kwezilingo ezingu-19 ezahlukene.

Abalobi balolu cwaningo baphetha ngokuthi i-glucosamine hydrochloride ayinenzuzo ekunciphiseni ubuhlungu (njengesivivinyo se-GAIT).

Kodwa-ke, ukuphakama okukhulu kwe-glucosamine sulfate (1500mg ngosuku) kungaba nemiphumela yokuguqula ukusebenza lapho kuthathwa izinyanga ezingaphezu kwezinyanga eziyisithupha. Imiphumela yokuguqula ukusebenza isho ukuthi i-glucosamine sulfate ingathuthukisa ikhono lomuntu lokusebenzisa amadolo (noma amadolo) nge-osteoarthritis.

I-Tidbit # 5: Okushiwo yi-American College of Rheumatology Mayelana Ne-Glucosamine

Ngokusho kwe-American College of Rheumatology, noma i-ACR, abantu abane-knee osteoarthritis akufanele basebenzise i-glucosamine. Kodwa-ke, lesi sincomo senziwe "esimweni esifanele," njengoba i-ACR ibona ukuthi ukusetshenziswa kwe-glucosamine kuseyingxabano.

Esikhundleni salokho, i-ACR itusa lokhu okulandelayo ukuphatha i-OA ngamadolo:

Izwi elivela

Ngenkathi isithembiso se-glucosamine njengendlela yokwelapha ehlukile ye-knee osteoarthritis engazange iphumelele kahle, abanye abantu bayayithatha futhi bayithole ukuthi iyabasebenza.

Ekugcineni, kungakhathaliseki uhlelo lwakho lwezokwelapha lwama-knee osteoarthritis, kubalulekile ukubona udokotela wakho ngokulandelelana okujwayelekile. Ngale ndlela ungashintsha izindlela zakho zokwelashwa njengoba impilo yakho ehlangene iguqukela futhi ucwaningo luyaqhubeka.

> Imithombo:

> Hochberg MC et al. I-American College of Rheumatology 2012 izincomo zokusetshenziswa kwe-nonpharmacologic kanye nemithi yokwelapha e-osteoarthritis yesandla, i-hip, namadolo. I-Arthritis Care Res (i-Hoboken) . 2012 Apr; 64 (4): 465-74.

> Jerosch J. Imiphumela ye-glucosamine ne-chrondroitin sulfate ekufakeni isifo samathambo e-OA: Ukubuka abanye abalingani bokudla okunomsoco ikakhulukazi ama-omega-3 fatty acids. I-Int J Rheumatol . 2011; 2011: 969012.

> Isikhungo Sikazwelonke seMpilo Ephelele kanye Nezohlanganiswa. (2014). I-Glucosamine ne-Chondroitin ye-Osteoarthritis.

> Wu D, Huang Y, Gu Y, Fan W. Ukusebenza kwamalungiselelo ahlukene we-glucosamine ekwelapheni i-osteoarthritis: ukuhlaziywa kwe-meta-ukuhlaziywa okulawulwa ngokungahleliwe, kokubili okuyimpumputhe, okulawulwa yi-placebo. I-Int J Clin Pract. 2014 Jun; 67 (6): 585-94.